Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

ANIP

0.00

Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Hold rating and announces Price Target of $91.